Monday, September 28, 2015
French drugmaker Sanofi said the European Commission had cleared its key cholesterol drug Praluent for the treatment of so-called "bad cholesterol," or low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia.
The drug won U.S. regulatory approval in July.
reuters.com
